ClinicalTrials.gg
CompletedNCT06895356Updated Jun 26, 2025

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

A Phase 1 interventional study of Tavapadon in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will assess the relative bioavailability of two different Oral formulations of tavapadon in healthy adult participants.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at the time of screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead
  • Females, Non- due to meeting the following criteria:

    • Permanent sterility due to a hysterectomy, bilateral salpingectomy, bilateral oophorectomy.
    • Non-surgical permanent infertility due to Mullerian agenesis, androgen insensitivity, or gonadal dysgenesis; investigator discretion should be applied to determining study entry.
    • female who is age ≤ 55 years with no menses for 12 or more months without an alternative medical cause AND a follicle-stimulating hormone (FSH) level ≥ 30 IU/L.

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy, any cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • History of suicidal ideation within one year prior to study drug administration as evidenced by answering "yes" to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity rating scale (C-SSRS) completed at Screening, or any history of suicide attempts within the last two years.
  • Use of tobacco- or nicotine-containing products within 90 days prior to the first dose of study treatment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Tavapadon: Part 1-Sequence 1

    Participants will receive Clinical Tavapadon Dose A in Period 1, followed by Commercial Tavapadon Dose B in Period 2

    Drug: Tavapadon

  • Experimental
    Tavapadon: Part 1-Sequence 2

    Participants will receive Commercial Clinical Tavapadon Dose B in Period 1, followed by Clinical Tavapadon Dose A in Period 2

    Drug: Tavapadon

  • Experimental
    Tavapadon: Part 2-Sequence 1

    Participants will receive Clinical Tavapadon Dose C in Period 1, Clinical Tavapadon Dose D in Period 2 followed by Commercial Tavapadon Dose E in Period 3

    Drug: Tavapadon

  • Experimental
    Tavapadon: Part 2-Sequence 2

    Participants will receive Clinical Tavapadon Dose C in Period 1, Commercial Tavapadon Dose E in Period 2 followed by Clinical Tavapadon Dose D in Period 3

    Drug: Tavapadon

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events

    An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment

    Time frame: Up to approximately 53 days

  2. Maximum Observed Plasma Concentration (Cmax) of Tavapadon

    (Cmax) of Tavapadon

    Time frame: Up to approximately 22 days

  3. Time to Cmax (Tmax) of Tavapadon

    Tmax of Tavapadon

    Time frame: Up to approximately 22 days

  4. Apparent Terminal Phase Elimination Rate Constant (β) of Tavapadon

    Apparent Terminal Phase Elimination Rate Constant (β) of Tavapadon

    Time frame: Up to approximately 22 days

  5. Terminal Phase Elimination Half-life (t1/2) of Tavapadon

    Terminal Phase Elimination Half-life (t1/2) of Tavapadon

    Time frame: Up to approximately 22 days

  6. Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Tavapadon

    Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Tavapadon

    Time frame: Up to approximately 22 days

  7. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of Tavapadon

    Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of Tavapadon

    Time frame: Up to approximately 22 days

  8. Trough Concentration (Ctrough) of Tavapadon

    Trough Concentration (Ctrough) of Tavapadon

    Time frame: Up to approximately 22 days

07

Study locations

1 site
  • Acpru /Id# 275870
    Grayslake, Illinois 60030, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Jun 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2025
First posted
Mar 26, 2025
StartActual
Mar 26, 2025
Primary completionActual
Jun 16, 2025
CompletionActual
Jun 16, 2025
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06895356
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 26, 2025
Start date
Mar 26, 2025
Primary completion
Jun 16, 2025
Completion
Jun 16, 2025
Last update
Jun 26, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tavapadon

Start the discussion